Femasys reports 2022 net loss of $11.4M, revenue up 2.2% to $1.2M

FEMASYS INC

Net loss of $11.4M ($0.96 per share) vs $7.5M loss in 2021; cash $12.96M expected to fund into Q1 2024.
Revenue $1.21M (+2.2% YoY); gross margin fell to 63.4% from 68.6%.
R&D expenses rose 42% to $5.81M; G&A expenses rose 27% to $5.43M.
Commercial launches of FemCath (tubal evaluation) and FemCerv (tissue sampler) in late 2022.
Clinical progress: FemBloc Stage 2 enrollment complete; FemaSeed pivotal trial 25% enrolled.

item 2.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FEMASYS INC reported financial results for year ended December 31, 2022.

Period: year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, Femasys Inc. announced its financial results for the year ended December 31, 2022.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

FEMASYS INC: Reduced stockholder meeting quorum requirement to 33.4% (effective 2023-03-29).

Change: bylaw amendment
Effective: 2023-03-29

Exact text from the filing

On March 29, 2023, the Board of Directors of Femasys Inc. amended Section 5 of Article I of Femasys Inc.’s Amended and Restated Bylaws to reduce the quorum requirement for any meeting of stockholders to 33.4%.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-014662

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.